KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Account Payables (2018 - 2025)

Moderna (MRNA) has disclosed Change in Account Payables for 8 consecutive years, with $22.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 35.29% to $22.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$92.0 million, a 33.33% decrease, with the full-year FY2025 number at -$92.0 million, down 33.33% from a year prior.
  • Change in Account Payables was $22.0 million for Q4 2025 at Moderna, down from $89.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $179.0 million in Q3 2023 to a low of -$303.0 million in Q1 2024.
  • A 5-year average of $14.8 million and a median of $21.5 million in 2023 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 9000.0% in 2021; the steepest drop was 1000.0% in 2021.
  • Moderna's Change in Account Payables stood at $178.0 million in 2021, then fell by 15.17% to $151.0 million in 2022, then tumbled by 86.09% to $21.0 million in 2023, then skyrocketed by 61.9% to $34.0 million in 2024, then plummeted by 35.29% to $22.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Change in Account Payables are $22.0 million (Q4 2025), $89.0 million (Q3 2025), and -$47.0 million (Q2 2025).